Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 379

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 379
---
1, 2024, our Prophase March 2024 Loan of $0.3 million that bears interest of 6% per annum and due June 1, 2024, our Prophase April 2024 Loan issued in April 2024 of $0.3 million that bears interest of 6% per annum and due June 1, 2024, our Prophase May 2024 Loans issued in May 2024 totaling $0.8 million that bears interest of 6% per annum and due June 1, 2024 and July 1, 2024, our Prophase July 2024 Loans issued in July 2024 totaling $0.1 million that bears interest of 6% per annum and due September 14, 2024, September 24, 2024 and September 29, 2024, our Prophase August 2024 Loans issued in August 2024 totaling $0.1 million that bears interest of 6% per annum and due October 12, 2024 and October 13, 2024, our Hana Loan issued in August 2024 totaling $0.3 million that bears interest of 6% per annum and due September 30, 2024, our Hana August 2024 Loan issued in August 2024 totaling $0.6 million that bears interest of 6% per annum and due October 26, 2024, our loans with Amantes issued November 2024 totaling $0.7 million that bear interest of 6% per annum and due January 1, 2025 (the “November Amantes Loan”), our loan with Amantes issued in January 2025 of $0.3 million that bears interest of 6% per annum and due March 1, 2025 (the “2025 Amantes Loan”). See Capital Requirements , above for discussion of our commitments and contractual obligations. Additionally, in the future we may enter into agreements in the normal course of business with contract research organizations, contract manufacturing organizations and other vendors for research and

<div align='center'>203</div>

TABLE OF CONTENTS

development services for operating purposes, which are generally cancelable upon written notice. In addition, some third party CMOs have intellectual property, such as patents and/or know-how with an annual fee and royalty bearing license to its customers that forms part of the manufacturing agreement. These payments are therefore not included in our contractual obligations herein.